Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Nov 04, 2021 9:50 AM - Nov 05, 2021 5:00 PM

(US Eastern Standard Time)

Master Protocols and Complex Innovative Design

Innovating for Modernized Clinical Trials

Session 9: Clinical Research in a Global Pandemic: Lessons Learned for Drug Development

Session Chair(s)

Cristiana  Mayer, DRSC, PHD

Cristiana Mayer, DRSC, PHD

Head of Biostatistics, Johnson & Johnson Vision, United States

AnnCatherine M. Downing, PHARMD

AnnCatherine M. Downing, PHARMD

Chief Operating Officer - Lilly Research Laboratories, Eli Lilly and Company, United States

Rui (Sammi)  Tang

Rui (Sammi) Tang

Vice President, Global Head of Biometrics, Servier Pharmaceuticals, United States

Traditional ethical principles that guide clinical research remain the guiding compass for physicians, patients, public health officials, investigators, drug developers, and the public. Accelerating the process of delivering safe and effective treatments and vaccines for areas of unmet medical need is a moral imperative. The COVID-19 pandemic has resulted in innovative new approaches in clinical research and brought vaccine and drug development into mainstream consciousness. Some of the innovations offer new insights into trial design, conduct, data sharing, and regulatory interactions that are broadly applicable. This session will highlight COVID-19 clinical research examples with an emphasis on practices that should be carried forward to speed new therapies to patients.

Learning Objective :
  • Outline multiple research efforts for the prevention and treatment of COVID-19
  • Describe innovative approaches utilized and found most efficient driven by the COVID-19 pandemic
  • Identify transferable learnings from COVID-19 research into other research programs

Speaker(s)

An  Vandebosch, PHD

An Vandebosch, PHD

Senior Scientific Director, Statistical Modeling and Methodology, Janssen R&D, Belgium

The Race Towards the COVID-19 Vaccine: the Janssen Example

Kristi  Huntington, MS

Kristi Huntington, MS

Sr. Advisor, Pharmaceutical Project Management, Eli Lilly and Company, United States

Developing a Neutralizing Antibody Treatment for COVID-19: Lessons Learned on the Journey from Discovery to Emergency Use Authorization

Lisa  LaVange, PHD

Lisa LaVange, PHD

Professor Emerita, University of North Carolina at Chapel Hill, United States

Master Protocols in a Pandemic

Steve  Webb, MD, PHD

Steve Webb, MD, PHD

Professor of Critical Care Research, Monash University, Australia

REAMP-CAP: An Adaptive Platform Trial Simultaneously Evaluating Multiple Interventions for Severe COVID

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.